Background: The treatment of trigeminal neuralgia (TN) involves first- and second-generation anticonvulsants. However, side effects (SEs) impair compliance with treatment, especially in elderly patients. Lacosamide (LCM) is a third-generation anticonvulsant with a mechanism of action that is not completely clear. It has few SEs and has been considered in the treatment of neuropathic pain. Clinical presentation: LCM was prescribed as a monotherapy for a 60-year-old female with TN who had proven refractory to previous treatments in terms of both the absence of any pain relief and the appearance of severe leukopenia. The treatment dosage was 100 mg twice daily. Pain relief was obtained after three weeks of treatment without any SEs. Currently, the patient takes a maintenance dosage of 100 mg/daily, remaining in a state of complete well-being. Conclusion: LCM has shown evidence of a potential efficacy and a good safety profile in the treatment of this patient with TN.
Lacosamide in trigeminal neuralgia: report of a case refractory to first- and second-generation anticonvulsants / Adamo, Daniela; Coppola, Noemi; Pecoraro, Giuseppe; Nicolo, Michele; Mignogna, Michele Davide. - In: CRANIO. - ISSN 0886-9634. - 41:2(2023), pp. 126-130. [10.1080/08869634.2020.1804233]
Lacosamide in trigeminal neuralgia: report of a case refractory to first- and second-generation anticonvulsants
Coppola, Noemi;Nicolo, Michele;Mignogna, Michele Davide
2023
Abstract
Background: The treatment of trigeminal neuralgia (TN) involves first- and second-generation anticonvulsants. However, side effects (SEs) impair compliance with treatment, especially in elderly patients. Lacosamide (LCM) is a third-generation anticonvulsant with a mechanism of action that is not completely clear. It has few SEs and has been considered in the treatment of neuropathic pain. Clinical presentation: LCM was prescribed as a monotherapy for a 60-year-old female with TN who had proven refractory to previous treatments in terms of both the absence of any pain relief and the appearance of severe leukopenia. The treatment dosage was 100 mg twice daily. Pain relief was obtained after three weeks of treatment without any SEs. Currently, the patient takes a maintenance dosage of 100 mg/daily, remaining in a state of complete well-being. Conclusion: LCM has shown evidence of a potential efficacy and a good safety profile in the treatment of this patient with TN.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
